Literature DB >> 16529002

[Nephrotic syndrome after extended thymectomy for thymoma with myasthenia gravis; report of a case].

T Yoshida1, T Suzuki, S Suzuki, M Masuda, R Usuda, H Tanaka, Y Inoue, A Yoshimura.   

Abstract

A 35-year-old man visited our hospital complaining of blepharoptosis and fatigability of the left arm. Under a diagnosis of myasthenia gravis (Osserman Ila), ambenonium was administered and improvements were noted. At 40-year-old, the patient underwent extended thymectomy due to the development of thymoma, which invaded the lung and pericardium (Masaoka stage Ill). Then ADOC therapy (doxorubicin hydrochloride+cisplatin+vincristine sulfate+cyclophosphamide) was initiated. At 47-year-old, we found recurrence of disseminated thymoma in thoracic cavity. Because of multiple metastatic lesions, radiotherapy in combination with chemotherapy was chosen and these lesions were reduced in size. Facial and foot edema developed at 50-year-old. Chest X-ray revealed bilateral pleural effusion. He was diagnosed as minimal change nephrotic syndrome and steroid therapy was started. The changes in cellular immunity due to thymoma is considered to be causative in the development of nephrotic syndrome. We report the clinical course of our case and discuss with reference to the literature.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16529002

Source DB:  PubMed          Journal:  Kyobu Geka        ISSN: 0021-5252


  3 in total

1.  Secondary membranous nephropathy in a patient with myasthenia gravis without thymic disease, and partial remission induced by adrenocorticotropic hormone therapy.

Authors:  Ramy M Hanna; Farid Arman; Umut Selamet; William D Wallace; Marina Barsoum; Anjay Rastogi; Niloofar Nobakht; Perry Shieh
Journal:  SAGE Open Med Case Rep       Date:  2019-08-08

2.  Nephrotic syndrome after thymectomy for myasthenia gravis.

Authors:  V B Kute; P R Shah; J D Shrimali; M R Gumber; H V Patel; A V Vanikar; H L Trivedi
Journal:  Indian J Nephrol       Date:  2013-01

Review 3.  Minimal change disease in a patient with myasthenia gravis: A case report.

Authors:  Jun-Li Tsai; Shang-Feng Tsai
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.